Pharmacological management of acute and persistent aggression in forensic psychiatry settings

CNS Drugs

Volumn 25, Issue 12, 2011, Pages 1009-1021

  Citrome, Leslie ^a   Volavka, Jan ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggression; Antidepressants; Antipsychotics; Benzodiazepines; Beta adrenergic receptor antagonists; Valproic acid.

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; LORAZEPAM; LOXAPINE; MIDAZOLAM; NADOLOL; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PHENYTOIN; PROMETHAZINE; QUETIAPINE; RISPERIDONE; S ADENOSYLMETHIONINE; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL;

ACUTE PSYCHOSIS; AGGRESSION; AGRANULOCYTOSIS; AKATHISIA; ARTICLE; COGNITIVE DEFECT; COGNITIVE THERAPY; DELUSION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DYSTONIA; ENVIRONMENTAL FACTOR; EPILEPTIC STATE; EXTRAPYRAMIDAL SYMPTOM; FORENSIC PSYCHIATRY; HOSTILITY; HUMAN; HYPOTENSION; IMPULSIVENESS; INTOXICATION; MANIA; NICOTINE REPLACEMENT THERAPY; ORTHOSTATIC HYPOTENSION; PARANOIA; PATIENT COMPLIANCE; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOPATHY; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYNCOPE; TACHYCARDIA; VIOLENCE;

AGGRESSION; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FORENSIC PSYCHIATRY; HUMANS; PERSONALITY DISORDERS; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA;

EID: 82555180468     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11596930-000000000-00000     Document Type: Article

References (84)

1. Citrome L, Volavka J. Treatment of violent behavior. In: Tasman A, Lieberman J, Kay J, editors. Psychiatry. 2nd ed. Chichester: John Wiley and Sons, 2003
2. Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract 2008; 62 (8): 1237-45 (Pubitemid 351977615)
3. Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 1988; 49 (12 Suppl.): 13-5 (Pubitemid 19020876)
4. Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68 (1): 57-63 (Pubitemid 9061001)
5. Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982; 71 (2): 248-52 (Pubitemid 12112857)
6. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev 2010 Apr 14; (4): CD007445
7. Man PL, Chen CH. Rapid tranqulization of acutely psychotic patients with intramuscular haloperidol and chlor-promazine. Psychosomatics 1973; 14 (1): 59-63
8. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15 (4): 335-40 (Pubitemid 27284198)
9. Huf G, Alexander J, Allen MH, et al. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 2009 Jul 8; (3): CD005146
10. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68 (12): 1876-85
11. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62 (1): 12-8 (Pubitemid 32154312)
12. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155 (2): 128-34 (Pubitemid 32417820)
13. Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005; 27 (2): 140-4 (Pubitemid 40348779)
14. Pfizer, Inc. Geodon (ziprasidone HCl) capsules, Geodon (ziprasidone mesylate) for injection for IM use only: product information revised December 2010 online. Available from URL: http://www.pfizer.com/pfizer/download/uspi- geodon.pdf. Accessed 2011 Jul 17
15. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158 (7): 1149-51 (Pubitemid 32623122)
16. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59 (5): 441-8 (Pubitemid 34477680)
17. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21 (4): 389-97 (Pubitemid 32673028)
18. Eli Lilly and Co. Zyprexa (olanzapine) tablets, Zyprexa Zydis (olanzapine) orally disintegrating tablets, Zyprexa IntraMuscular (olanzapine) for injection: product information revised June 2011 online. Available from URL: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed 2011 Jul 17
19. San L, Arranz B, Querejeta I, et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006; 21 (8): 539-43 (Pubitemid 44855528)
20. Marder SR, Sorsaburu S, Dunayevich E, et al. Case reports of postmarketing adverse event experiences with olanza-pine intramuscular treatment in patients with agitation. J Clin Psychiatry 2010; 71 (4): 433-41
21. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188 (3): 281-92 (Pubitemid 44387456)
22. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68 (1): 111-9 (Pubitemid 46220132)
23. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psycho-pharmacol 2007; 27 (2): 171-6 (Pubitemid 46594934)
24. Bristol-Myers Squibb. Abilify (aripiprazole) tablets, Abilify (aripiprazole) DiscMelt orally disintegrating tablets, Abil-ify (aripiprazole) oral solution, Abilify (aripiprazole) injection for intramuscular use only: product information revised February 2011 online. Available from URL: http://www.abilify.com/pdf/pi.aspx Accessed 2011 Jul 17
25. Citrome L. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract 2011; 65 (3): 330-40
26. Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. Epub 2011 Jan 25
27. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198 (1): 51-8
28. Fishman R, Cassella J, Spyker D, AZ-004 Study Group. Inhaled loxapine rapidly improves acute agitation in patients with bipolar disorder poster presentation, NR7-006. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco (CA)
29. Currier GW, Chou JCY, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65 (3): 386-94
30. Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psycho-pharmacol 2003; 23 (4): 342-8 (Pubitemid 36951175)
31. Hsu WY, Huang SS, Lee BS, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular halo-peridol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 2010; 30 (3): 230-4
32. Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (2): 405-13 (Pubitemid 351210624)
33. Allen MH, Debanne M, Lazignac C, et al. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2011; 168 (4): 395-9
34. Citrome L, Nolan KA, Volavka J. Science-based treatment of aggression and agitation. In: Fishbein D, editor. The science, treatment, and prevention of antisocial behaviors. Vol 2. Kingston (NJ): Civic Research Institute, 2004
35. Haddock G, Barrowclough C, Shaw JJ, et al. Cognitivebehavioural therapy v. Social activity therapy for people with psychosis and a history of violence: randomised controlled trial. Br J Psychiatry 2009; 194 (2): 152-7
36. Yates KF, Kunz M, Khan A, et al. Psychiatric patients with histories of aggression and crime five years after discharge from a cognitive-behavioral program. J Forensic Psychiatry Psychol 2010; 21 (2): 167-88
37. Nolan KA, Citrome L. Reducing inpatient aggression: does paying attention pay off? Psychiatr Q 2008; 79 (2): 91-5 (Pubitemid 351748182)
38. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373 (9657): 31-41
39. Leucht S, Komossa K, Rummel-Kluge C, et al. A metaanalysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166 (2): 152-63
40. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Exp Opin Pharma-cotherapy. In press
41. Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psycho-pharmacol 1993; 13 (4): 287-9 (Pubitemid 23265171)
42. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52 (11): 1510-4 (Pubitemid 33029591)
43. Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004; 24 (2): 225-8 (Pubitemid 38380848)
44. Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006; 63 (6): 622-9 (Pubitemid 43848293)
45. Maccall C, Billcliff N, Igbrude W, et al. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol 2009; 23 (2): 206-10
46. Eap CB, Bender S, Jaquenoud SE, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004; 24 (2): 214-9 (Pubitemid 38380846)
47. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15 (4): 243-9
48. Kinon BJ, Roychowdhury SM, Milton DR, et al. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001; 62 Suppl. 2: 17-21 (Pubitemid 32154136)
49. Chengappa KN, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25 (2): 530-41 (Pubitemid 36286918)
50. Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 2005; 20 (4): 237-41 (Pubitemid 40873461)
51. Citrome L, Volavka J, Czobor P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 2006; 67 (4): 638-42 (Pubitemid 43764241)
52. Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schi-zoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry 2005; 66 (11): 1362-6 (Pubitemid 41779532)
53. Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 2007; 68 (5): 662-8 (Pubitemid 46841848)
54. Citrome L, Casey DE, Daniel DG, et al. Effects of adjunctive valproate on hostility in patients with schizophrenia receiving olanzapine or risperidone: a double-blind multi-center study. Psychiatr Serv 2004; 55 (3): 290-4
55. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209-23 (Pubitemid 41345943)
56. Swanson JW, Swartz MS, Van Dorn RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry 2008; 193 (1): 37-43 (Pubitemid 351946806)
57. Swanson JW, Van Dorn RA, Swartz MS, et al. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav 2008; 32 (3): 228-40 (Pubitemid 351692047)
58. Volavka J, Citrome L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull 2011; 37 (5): 921-9
59. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62 (3): 199-203 (Pubitemid 32270095)
60. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo controlled crossover design. Am J Psychiatry 2000; 157 (6): 818-20 (Pubitemid 30249664)
61. Citrome L, Shope CB, Nolan KA, et al. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psycho-pharmacol 2007; 22 (6): 356-62 (Pubitemid 47530840)
62. Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002; 17 (6): 579-85 (Pubitemid 34678711)
63. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155 (1): 54-61 (Pubitemid 28037549)
64. Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 1991; 84 (2): 150-4
65. Sheard MH, Marini JL, Bridges CI, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133 (12): 1409-13
66. Ratey JJ, Sorgi P, O'Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53 (2): 41-6
67. Alpert M, Allan ER, Citrome L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26 (3): 367-71 (Pubitemid 20386911)
68. Caspi N, Modai I, Barak P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001; 16 (2): 111-5 (Pubitemid 32171836)
69. Karson CN, Weinberger DR, Bigelow L, et al. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 1982; 139 (12): 1627-8 (Pubitemid 13204471)
70. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91 (5): 348-51
71. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54 (12): 1081-8 (Pubitemid 27524373)
72. Strous RD, Ritsner MS, Adler S, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 2009; 19 (1): 14-22
73. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51 (5): 634-8 (Pubitemid 30256639)
74. Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother 2009; 9 (1): 55-71
75. Huband N, Ferriter M, Nathan R, et al. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010 Feb 17; (2): CD003499
76. Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res 1999; 35 Suppl.: S23-33 (Pubitemid 29133023)
77. Alia-Klein N, O'Rourke TM, Goldstein RZ, et al. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav 2007; 33 (1): 86-96
78. Arango C, Bombin I, Gonzalez-Salvador T, et al. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006; 21 (1): 34-40 (Pubitemid 43245596)
79. Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63 (6): 669-78 (Pubitemid 43848298)
80. Coccaro EF, Lee RJ, Kavoussi RJ. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009; 70 (5): 653-62
81. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in Cluster B personality disorders. Neuropsychopharmacology 2003; 28 (6): 1186-97
82. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162 (3): 621-4 (Pubitemid 40343936)
83. Latalova K. Bipolar disorder and aggression. Int J Clin Pract 2009; 63 (6): 889-99
84. Swann AC, Bowden CL, Calabrese JR, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002; 26 (4): 530-6 (Pubitemid 34261002)